Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corvus Pharmaceuticals Inc CRVS

Healthcare Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in... see more

Recent & Breaking News (NDAQ:CRVS)

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

GlobeNewswire April 20, 2023

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire April 17, 2023

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

GlobeNewswire April 3, 2023

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 28, 2023

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

GlobeNewswire March 21, 2023

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 14, 2023

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818's (ITK Inhibitor) Potential to Block HIV Latency Reversal

GlobeNewswire February 21, 2023

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire December 12, 2022

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

GlobeNewswire December 5, 2022

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

GlobeNewswire November 14, 2022

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire November 3, 2022

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

GlobeNewswire October 27, 2022

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

GlobeNewswire October 25, 2022

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

GlobeNewswire September 26, 2022

Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022

GlobeNewswire July 28, 2022

Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

GlobeNewswire July 21, 2022

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

GlobeNewswire May 10, 2022